BR112018069147A2 - composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh - Google Patents

composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh

Info

Publication number
BR112018069147A2
BR112018069147A2 BR112018069147A BR112018069147A BR112018069147A2 BR 112018069147 A2 BR112018069147 A2 BR 112018069147A2 BR 112018069147 A BR112018069147 A BR 112018069147A BR 112018069147 A BR112018069147 A BR 112018069147A BR 112018069147 A2 BR112018069147 A2 BR 112018069147A2
Authority
BR
Brazil
Prior art keywords
fimh
treating
compound
pharmaceutical composition
formula iii
Prior art date
Application number
BR112018069147A
Other languages
English (en)
Portuguese (pt)
Inventor
W Janetka James
Mydock-Mcgrane Laurel
Original Assignee
Fimbrion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fimbrion Therapeutics Inc filed Critical Fimbrion Therapeutics Inc
Publication of BR112018069147A2 publication Critical patent/BR112018069147A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Composite Materials (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018069147A 2016-03-23 2017-03-23 composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh BR112018069147A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662312017P 2016-03-23 2016-03-23
PCT/US2017/023764 WO2017165619A1 (en) 2016-03-23 2017-03-23 Mannose-derived antagonists of fimh useful for treating disease

Publications (1)

Publication Number Publication Date
BR112018069147A2 true BR112018069147A2 (pt) 2019-01-22

Family

ID=59900869

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069147A BR112018069147A2 (pt) 2016-03-23 2017-03-23 composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh

Country Status (10)

Country Link
US (3) US10738070B2 (enExample)
EP (1) EP3432892A4 (enExample)
JP (1) JP2019509315A (enExample)
KR (1) KR20180128937A (enExample)
CN (1) CN108778288A (enExample)
AU (1) AU2017238392A1 (enExample)
BR (1) BR112018069147A2 (enExample)
CA (1) CA3018345A1 (enExample)
RU (1) RU2018131440A (enExample)
WO (1) WO2017165619A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180128937A (ko) 2016-03-23 2018-12-04 핌브리온 세러퓨틱스 인코포레이티드 질환을 치료하는데 유용한 fimh의 만노스-유래 길항제
US10385087B1 (en) * 2018-04-26 2019-08-20 National Taipei University Of Technology Xylose derivatives and process for preparation thereof
DK3820856T3 (da) 2018-07-10 2022-10-24 Glaxosmithkline Ip Dev Ltd C-Mannosid-forbindelser, der kan anvendes til behandling af urinvejsinfektioner
BR112021022281A2 (pt) 2019-05-07 2021-12-28 Fimbrion Therapeutics Inc Novos compostos
WO2020254369A1 (en) * 2019-06-19 2020-12-24 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of fimh
CN111205344B (zh) * 2020-01-14 2023-03-14 华东理工大学 一种用于甲醇溶剂识别的纯有机磷光小分子材料及其制备方法
WO2021197363A1 (zh) * 2020-03-31 2021-10-07 苏州大学 2-炔基甘露糖衍生物及其应用
CN111518738B (zh) * 2020-05-08 2022-02-08 徐州海润生物科技有限公司 重组卡介苗及其制备方法和应用
CN113797212B (zh) * 2020-06-11 2023-12-22 兰州大学 一组含有甘露糖结构的抗菌药物的合成方法及活性研究
CN116621891B (zh) * 2023-05-25 2023-10-31 齐齐哈尔医学院 白鲜酚苷c及其制备方法和其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
DK0730601T3 (da) 1993-11-18 2005-06-06 Univ Washington Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner
AU7470300A (en) 1999-08-11 2001-03-05 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
US6719991B2 (en) 2000-06-09 2004-04-13 Baylor College Of Medicine Combination of antimicrobial agents and bacterial interference to coat medical devices
US7265245B2 (en) 2003-10-08 2007-09-04 Innovaprotean, S.L Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
SG181115A1 (en) * 2009-12-14 2012-07-30 Univ Basel Mannose derivatives as antagonists of bacterial adhesion
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
HK1213268A1 (zh) * 2013-03-12 2016-06-30 沃泰克斯药物股份有限公司 用於治療細菌感染的甘露糖衍生物
EP3003322B1 (en) 2013-05-30 2023-09-13 Washington University Mannose derivatives and their use in the treatment of bacterial infections
US20200002303A1 (en) 2016-03-11 2020-01-02 Fimbrion Therapeutics, Inc. C-glycoside compounds useful for treating disease
KR20180128937A (ko) 2016-03-23 2018-12-04 핌브리온 세러퓨틱스 인코포레이티드 질환을 치료하는데 유용한 fimh의 만노스-유래 길항제

Also Published As

Publication number Publication date
US20190106451A1 (en) 2019-04-11
RU2018131440A (ru) 2020-04-23
US20250009723A1 (en) 2025-01-09
US20200407390A1 (en) 2020-12-31
CN108778288A (zh) 2018-11-09
EP3432892A1 (en) 2019-01-30
AU2017238392A1 (en) 2018-09-27
KR20180128937A (ko) 2018-12-04
RU2018131440A3 (enExample) 2020-05-18
EP3432892A4 (en) 2019-10-30
WO2017165619A1 (en) 2017-09-28
US10738070B2 (en) 2020-08-11
JP2019509315A (ja) 2019-04-04
CA3018345A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
BR112018069147A2 (pt) composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
BR112017013258A8 (pt) Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidina-2,4-diona como inibidores de adamts para o tratamento de osteoartrite
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
MX380092B (es) Tratamiento de la osteoartritis.
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
BR112018010113A2 (pt) composto, composição, e, métodos para inibir acc, para tratar uma infecção fúngica, parasítica ou bacteriana e para controlar patógenos fúngicos agrícolas
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
BR112018008227A2 (pt) ?composto, composição, e, métodos para inibir acc, para tratar um distúrbio metabólico, um câncer ou outro distúrbio proliferativo, uma infecção fúngica, parasítica ou bacteriana e para controlar patógenos fúngicos agrícolas?
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
BR112019012062A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
BR112018009911A2 (pt) composto, composição, e, métodos para inibir acc, para tratar uma infecção fúngica, parasítica ou bacteriana e para controlar patógenos fúngicos agrícolas.
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
BR112017009657A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112013024171A2 (pt) método para o tratamento e prevenção de uma condição neurodegenerativa
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
MX385138B (es) Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes.
BR112015017878A2 (pt) composto da fórmula estrutural ii, composto da fórmula estrutural iii, composição farmacêutica e método de tratamento de um distúrbio mediado por vmat2
MX389771B (es) Compuestos de minociclina para biodefensas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements